A European perspective on topical ophthalmic antibiotics: current and evolving options.

D Bremond-Gignac, F Chiambaretta, S Milazzo
Author Information
  1. D Bremond-Gignac: Ophthalmology Department, Centre St Victor, University Hospital of Amiens, Picardie Jules Verne University, Amiens, France. ; INSERM UMRS968, Vision Institute, Paris 7 University, France.

Abstract

BACKGROUND: Eye infections can be vision-threatening and must be treated effectively by appropriate and safe use of topical ophthalmic anti-infectives. This review will essentially consider the current and evolving treatment options for the various types of bacterial eye infections. Ocular surface bacterial infections affect subjects of all ages with a high frequency in newborns and children.
METHODS: This article presents a review of the peer-reviewed published scientific literature in order to define the well-established uses of anti-infective eye drops in the field of ocular infections. A comprehensive search of the recent published literature including topical ophthalmic anti-infectives effective in bacterial ocular infections was performed. Clinical studies provide relevant data concerning the characteristics and clinical efficacy of antibacterial eye drops in ocular anterior segment infections or for perioperative prophylaxis. Publications were included to cover the current options of antibacterial eye drops available in Europe.
RESULTS: Several recent publications identified effective topical ocular antibacterials requiring a reduced dose regimen and a short treatment course. Additional literature reviewed included data on novel perioperative prophylaxis, indications for topical fortified antibiotics and innovative research including the risk of resistance.
CONCLUSIONS: Safe and effective topical antibiotic eye drops for the treatment and prevention of ocular infections must be adapted to the type of bacteria suspected. Usual topical antimicrobials should be replaced by more recent and more effective treatments. The use of highly effective fluoroquinolones should be reserved for the most severe cases to avoid resistance. Short treatment courses, such as azithromycin, can be easily used in children, thereby improving quality of life.

Keywords

References

  1. Antimicrob Agents Chemother. 2000 Jun;44(6):1650-4 [PMID: 10817723]
  2. West J Med. 1994 Dec;161(6):579-84 [PMID: 7856158]
  3. Invest Ophthalmol Vis Sci. 2010 Jan;51(1):362-8 [PMID: 19684005]
  4. J Cataract Refract Surg. 2007 Jun;33(6):978-88 [PMID: 17531690]
  5. Ophthalmology. 2002 Jan;109(1):13-24 [PMID: 11772573]
  6. Eye (Lond). 2009 Dec;23(12):2187-93 [PMID: 19218994]
  7. Acta Ophthalmol Scand. 2005 Feb;83(1):7-10 [PMID: 15715550]
  8. Br J Ophthalmol. 2003 Jul;87(7):834-8 [PMID: 12812878]
  9. J Cataract Refract Surg. 2010 Feb;36(2):286-9 [PMID: 20152612]
  10. Am J Ophthalmol. 2008 May;145(5):879-82 [PMID: 18329624]
  11. J Cataract Refract Surg. 1999 Jan;25(1):65-71 [PMID: 9888079]
  12. J Antimicrob Chemother. 2008 Jan;61(1):26-38 [PMID: 17986491]
  13. Exp Eye Res. 2004 Mar;78(3):361-5 [PMID: 15106913]
  14. J Antimicrob Chemother. 1993 Jan;31(1):139-50 [PMID: 8383102]
  15. Am J Respir Crit Care Med. 2003 Sep 1;168(5):581-7 [PMID: 12829454]
  16. J Cataract Refract Surg. 2010 Feb;36(2):203-7 [PMID: 20152598]
  17. PLoS One. 2009 Jun 05;4(6):e5806 [PMID: 19503797]
  18. Ophthalmology. 1991 Dec;98(12):1769-75 [PMID: 1775308]
  19. Clin Ophthalmol. 2010 Apr 26;4:321-6 [PMID: 20463800]
  20. J Cataract Refract Surg. 2009 Jan;35(1):89-97 [PMID: 19101430]
  21. Eye (Lond). 2009 Feb;23(2):294-8 [PMID: 18188174]
  22. J Cataract Refract Surg. 2011 Feb;37(2):271-8 [PMID: 21241909]
  23. Ann Ophthalmol (Skokie). 2008 Summer;40(2):68-74 [PMID: 19013912]
  24. Ophthalmology. 2009 Oct;116(10):1887-96.e1 [PMID: 19560825]
  25. Antimicrob Agents Chemother. 1999 Mar;43(3):705-7 [PMID: 10049296]
  26. Antimicrob Agents Chemother. 2004 Sep;48(9):3457-61 [PMID: 15328111]
  27. Clin Pharmacokinet. 1999 Nov;37(5):351-60 [PMID: 10589371]
  28. Basic Clin Pharmacol Toxicol. 2009 Jun;104(6):478-82 [PMID: 19389045]
  29. Cornea. 2000 Sep;19(5):650-8 [PMID: 11009317]
  30. Br J Ophthalmol. 2007 Apr;91(4):465-9 [PMID: 17050578]
  31. Arch Soc Esp Oftalmol. 2009 Feb;84(2):85-9 [PMID: 19253178]
  32. Ophthalmology. 2007 May;114(5):866-70 [PMID: 17324467]
  33. Ophthalmic Surg. 1995 May-Jun;26(3):233-6 [PMID: 7651690]
  34. Br J Ophthalmol. 2001 Apr;85(4):388-92 [PMID: 11264124]
  35. Retina. 2009 Oct;29(9):1213-7 [PMID: 19934815]
  36. J Antimicrob Chemother. 2005 Jan;55(1):10-21 [PMID: 15590715]
  37. Ophthalmology. 2002 Nov;109(11):2036-40; discussion 2040-1 [PMID: 12414411]
  38. Eur Respir J. 2004 May;23(5):671-8 [PMID: 15176678]
  39. Br J Gen Pract. 2005 Dec;55(521):962-4 [PMID: 16378567]
  40. Arch Ophthalmol. 2011 Apr;129(4):399-402 [PMID: 21482865]
  41. J Ocul Pharmacol Ther. 2010 Dec;26(6):587-9 [PMID: 21034244]
  42. Br J Ophthalmol. 2007 May;91(5):667-72 [PMID: 17005549]
  43. J Fr Ophtalmol. 2005 Feb;28(2):151-6 [PMID: 15851948]
  44. J Cataract Refract Surg. 2000 Nov;26(11):1620-5 [PMID: 11084269]
  45. Ocul Surf. 2004 Apr;2(2):149-65 [PMID: 17216085]
  46. Antimicrob Agents Chemother. 2002 Sep;46(9):2727-34 [PMID: 12183222]
  47. Can J Ophthalmol. 2002 Jun;37(4):228-37; discussion 237 [PMID: 12095096]
  48. Int J Antimicrob Agents. 2008 Jan;31(1):12-20 [PMID: 17935949]
  49. Eur J Ophthalmol. 2005 Sep-Oct;15(5):541-9 [PMID: 16167284]
  50. Br J Ophthalmol. 2010 Oct;94(10):1410-1 [PMID: 20710049]
  51. J Cataract Refract Surg. 2010 Sep;36(9):1588-98 [PMID: 20692574]
  52. Ophthalmology. 1990 Dec;97(12):1684-8 [PMID: 2087299]
  53. Antimicrob Agents Chemother. 1987 Dec;31(12):1939-47 [PMID: 2449865]
  54. Ophthalmology. 1996 May;103(5):842-6 [PMID: 8637698]
  55. Retina. 2009 May;29(5):601-5 [PMID: 19357558]
  56. Br J Ophthalmol. 1984 Aug;68(8):524-8 [PMID: 6743618]
  57. Curr Opin Ophthalmol. 2001 Feb;12(1):68-74 [PMID: 11150084]
  58. Surv Ophthalmol. 2001 Mar;45 Suppl 2:S211-20 [PMID: 11587145]
  59. Retina. 2008 Nov-Dec;28(10):1395-9 [PMID: 18827737]
  60. Ocul Surf. 2009 Apr;7(2 Suppl):S21-2 [PMID: 19445092]
  61. J Pediatr. 1993 Jan;122(1):10-4 [PMID: 8419593]
  62. Clin Pediatr (Phila). 1997 Aug;36(8):435-44 [PMID: 9272316]
  63. Arch Ophthalmol. 1998 Dec;116(12):1625-8 [PMID: 9869792]
  64. J Cataract Refract Surg. 2009 Apr;35(4):770-3 [PMID: 19304103]
  65. Ophthalmology. 1982 Oct;89(10):1173-80 [PMID: 6218459]
  66. Br J Ophthalmol. 1985 Aug;69(8):604-11 [PMID: 4016059]
  67. Curr Opin Infect Dis. 2007 Apr;20(2):129-41 [PMID: 17496570]
  68. Am J Ophthalmol. 2007 Sep;144(3):454-6 [PMID: 17765429]
  69. J Fr Ophtalmol. 2007 Oct;30(8):807-13 [PMID: 17978677]
  70. Cornea. 2000 Sep;19(5):659-72 [PMID: 11009318]
  71. Clin Infect Dis. 2002 Feb 15;34(4):482-92 [PMID: 11797175]
  72. J Cataract Refract Surg. 2008 Mar;34(3):447-51 [PMID: 18299070]
  73. J Cataract Refract Surg. 2002 Jun;28(6):982-7 [PMID: 12036640]
  74. J Cataract Refract Surg. 2007 Oct;33(10):1801-5 [PMID: 17889779]
  75. Retina. 2008 Apr;28(4):564-7 [PMID: 18398358]
  76. J Cataract Refract Surg. 2002 Jun;28(6):977-81 [PMID: 12036639]
  77. Br J Ophthalmol. 1990 Aug;74(8):477-80 [PMID: 2390523]
  78. J Infect. 2004 Aug;49(2):109-14 [PMID: 15236917]
  79. Adv Ther. 2008 Sep;25(9):858-70 [PMID: 18781287]
  80. J Fr Ophtalmol. 1992;15(12):669-78 [PMID: 1299678]
  81. J Fr Ophtalmol. 2005 Dec;28(10):1122-30 [PMID: 16395208]
  82. Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4074-9 [PMID: 11095598]
  83. Ophthalmology. 2003 Mar;110(3):457-65 [PMID: 12623805]
  84. An Pediatr (Barc). 2004 Jul;61(1):32-6 [PMID: 15228931]
  85. J Ocul Pharmacol Ther. 2008 Feb;24(1):1-7 [PMID: 18370872]
  86. J Fr Ophtalmol. 2010 Oct;33(8):551-5 [PMID: 20843579]
  87. J Lab Clin Med. 2001 Mar;137(3):176-83 [PMID: 11241027]
  88. BMJ. 2004 Jul 24;329(7459):206-10 [PMID: 15201195]
  89. Clin Ophthalmol. 2010 Jul 30;4:681-8 [PMID: 20689782]
  90. Pediatr Infect Dis J. 2010 Mar;29(3):222-6 [PMID: 19935122]
  91. Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2867-77 [PMID: 11687531]
  92. Br J Ophthalmol. 2003 Jul;87(7):805-6 [PMID: 12812870]
  93. Am J Ophthalmol. 2008 Jun;145(6):959-65 [PMID: 18374301]

Word Cloud

Created with Highcharts 10.0.0infectionstopicaleyetreatmentdropsoculareffectivebacterialophthalmiccurrentoptionschildrenliteraturerecentprophylaxiscanmustuseanti-infectivesreviewevolvingpublishedincludingdataantibacterialperioperativeincludedshortcourseresistanceazithromycinBACKGROUND:Eyevision-threateningtreatedeffectivelyappropriatesafewillessentiallyconsidervarioustypesOcularsurfaceaffectsubjectsageshighfrequencynewbornsMETHODS:articlepresentspeer-reviewedscientificorderdefinewell-establishedusesanti-infectivefieldcomprehensivesearchperformedClinicalstudiesproviderelevantconcerningcharacteristicsclinicalefficacyanteriorsegmentPublicationscoveravailableEuropeRESULTS:SeveralpublicationsidentifiedantibacterialsrequiringreduceddoseregimenAdditionalreviewednovelindicationsfortifiedantibioticsinnovativeresearchriskCONCLUSIONS:SafeantibioticpreventionadaptedtypebacteriasuspectedUsualantimicrobialsreplacedtreatmentshighlyfluoroquinolonesreservedseverecasesavoidShortcourseseasilyusedtherebyimprovingqualitylifeEuropeanperspectiveantibiotics:conjunctivitisendophthalmitisnewborn

Similar Articles

Cited By